# Lacosamide

## Vimpat Intravenous 200mg/20mL

| TAH Drug Code      | [**IVIM**](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IVIM)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Monotherapy for patients with localized seizures over the age of 4. Assistance to (1) complex partial seizure and (2) simple or complex partial seizure with secondary generalization over 4 years of age Add-on therapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Dosing             | Adults (17 years and older): Monotherapy: Initial Dosage: 100 mg twice daily (200 mg per day) Titration Regimen: Increase by 50 mg twice daily (100 mg per day) every week. Maintenance Dosage: 150 mg to 200 mg twice daily (300 mg to 400 mg per day). Adults (17 years and older): Adjunctive Therapy: Initial Dosage: 50 mg twice daily (100 mg per day) Titration Regimen: Increase by 50 mg twice daily (100 mg per day) every week. Maintenance Dosage: 100 mg to 200 mg twice daily (200 mg to 400 mg per day). Adults (17 years and older): Alternate Initial Dosage: 200 mg single loading dose, followed 12 hours later by 100 mg twice daily. Pediatric patients weighing 50 kg or more: Initial Dosage: 50 mg twice daily (100 mg per day). Titration Regimen: Increase by 50 mg twice daily (100 mg per day) every week. Maintenance Dosage: Monotherapy: 150 mg to 200 mg twice daily (300 mg to 400 mg per day). Adjunctive Therapy: 100 mg to 200 mg twice daily (200 mg to 400 mg per day). Maximum recommended dose: 400 mg per day. |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Contraindications  | Allergic to the main ingredients or any excipients. second-or third-degree AV block.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Adverse Effects    | Common Gastrointestinal: Nausea (up to 24% ) Neurologic: Dizziness (Oral, 16% to 30% ; IV, 20% to 60% ), Headache (11% to 16% ) Ophthalmic: Diplopia (9% to 11% ) Serious Cardiovascular: Atrial fibrillation and flutter, First degree atrioventricular block, Asymptomatic (0.4% ), Prolonged PR interval Immunologic: Drug reaction with eosinophilia and systemic symptoms Psychiatric: Suicidal behavior, Suicidal thoughts                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Moderate Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

## Vimpat 100mg

| TAH Drug Code      | [**OVIM**](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OVIM)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Monotherapy for patients with localized seizures over the age of sixteen. Assistance to (1) complex partial seizure and (2) simple or complex partial seizure with secondary generalization over 4 years of age Add-on therapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Dosing             | Children and adolescents bodyweight >=50 kg and adults: Monotherapy and Adjunctive Therapy: Initial Dosage: 50 mg twice daily. One week later, the initial therapeutic dose was increased to 100 mg twice a day. According to response and tolerability, the maintenance dose can be increased by 50 mg twice a day (100 mg/day) per week, to the maximum recommended daily dose: 200 mg twice a day. Start treatment with a fast-acting dose of Lacosamide:200 mg as a single dose. After 12 hours,100 mg twice a day (200 mg/day) as a maintenance dose. Discontinue the drug: recommended to gradually reduce the dose (for example, reduce the daily dose by 200 mg/week). For patients with severe cardiac arrhythmia, clinical benefit/risk assessment should be performed, and Lacosamide should be discontinued if necessary. Switch from a single antiepileptic drug (AED) to Lacosamide monotherapy: The anti-epileptic drugs should not be discontinued until the therapeutic dose of Lacosamide is reached for at least 3 days. It is recommended to gradually stop using anti-epileptic drugs for at least 6 weeks. |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Contraindications  | Allergic to the main ingredients or any excipients. second-or third-degree AV block.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Adverse Effects    | Common Gastrointestinal: Nausea (up to 24% ) Neurologic: Dizziness (Oral, 16% to 30% ; IV, 20% to 60% ), Headache (11% to 16% ) Ophthalmic: Diplopia (9% to 11% ) Serious Cardiovascular: Atrial fibrillation and flutter, First degree atrioventricular block, Asymptomatic (0.4% ), Prolonged PR interval Immunologic: Drug reaction with eosinophilia and systemic symptoms Psychiatric: Suicidal behavior, Suicidal thoughts                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Moderate Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

